Skip to main content
SpringerLink
Log in

AbobotulinumtoxinA − benefits at acceptable cost in CD

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Ipsen Pharma.

  2. Toronto Western Spasmodic Torticollis Rating Scale

Reference

  • Muthukumar M, et al. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. ClinicoEconomics and Outcomes Research : 15 Apr 2017. Available from: URL: https://doi.org/10.2147/CEOR.S112254

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

AbobotulinumtoxinA − benefits at acceptable cost in CD. PharmacoEcon Outcomes News 777, 4 (2017). https://doi.org/10.1007/s40274-017-3943-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3943-6

Search

Navigation